Today we announced the decision of our partner Sanofi to expand our KT-474 Phase 2 studies in HS and AD following an interim review of safety and efficacy data to accelerate overall program timelines. Read the full press release here: https://bit.ly/4cyUBJg #RevolutionizingImmunology
Kymera Therapeutics
Biotechnology Research
Watertown, MA 28,934 followers
Inventing a new class of medicines using Targeted Protein Degradation
About us
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on delivering oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Kymera is also progressing degrader oncology programs that target undrugged or poorly drugged proteins to create new ways to fight cancer. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years.
- Website
-
http://www.kymeratx.com
External link for Kymera Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Watertown, MA
- Type
- Public Company
- Founded
- 2016
Locations
-
Primary
500 North Beacon Street
4th Floor
Watertown, MA 02472, US
Employees at Kymera Therapeutics
Updates
-
Don’t miss our CEO Nello Mainolfi's fireside chat at the UBS Virtual Targeted Protein Degradation Day next week! Learn more: https://bit.ly/4cxOyF0
-
-
We strive to give our team benefit offerings that go above and beyond, including an extended July 4th weekend to rest, recharge, and celebrate! Learn more & explore our current openings: https://bit.ly/3zv2DEq #Pioneer #Collaborate #Belong
-
-
Thank you to our colleagues, family, collaborators, and more who joined us to celebrate our expansion into a new space and our exciting progress and advancements! Our commitment to improving patient’s lives drives our work and connects our diverse, experienced, and passionate community to Kymera’s mission to revolutionize healthcare. #ReinventingMedicine
-
-
Our Senior Director of #Proteomics, Kirti Sharma, is the keynote speaker at the Life Sciences Switzerland (LS2) annual conference today and will discuss our toolbox of integrated approaches to accelerate the discovery and development of transformative degrader medicines. #DrugDiscovery #TPD #ReinventingMedicine
-
-
The historical legacy of #Juneteenth shows the value of never giving up hope in uncertain times and how small changes and individual voices can start a movement for freedom and equality. Today, we celebrate Freedom Day and recognize it as an official Kymera holiday to allow for education, reflection, celebration, and understanding. Learn more about this holiday here: https://bit.ly/3qTZhX8
-
-
Today we shared new clinical data being presented at the European Hematology Association (EHA) Annual Meeting from our ongoing KT-333 Phase 1 oncology trial. KT-333 is a potent, highly selective degrader of STAT3, a historically undrugged transcription factor, and new data shared from the trial shows clinical translation of our degrader’s profile across multiple diseases. Read the full press release and view the poster here: https://bit.ly/3VGZY35 #EHA2024 #TPD #ReinventingMedicine
-
Today, tune into a fireside chat with our CEO, Nello Mainolfi, at the Goldman Sachs Annual Global #Healthcare Conference where he’ll discuss the latest developments across our pipeline and what’s ahead for Kymera. Check out the live webcast here: https://bit.ly/3VbpIDb #TPD #Biotech
-
-
#HidradenitisSuppurativa is a chronic, painful skin disease whereby there remains a tremendous need for new treatment options for patients, and for #HSAwarenessWeek we hope to increase awareness and understanding for this debilitating disease. We’re driven to revolutionize the treatment of immuno-inflammatory diseases by building an industry leading pipeline of oral medicines - learn more about #KT474, currently in Phase 2 trials for HS and AD: https://bit.ly/3KCXz2Z #RevolutionizingImmunology
-
In honor of #PrideMonth, we were delighted to host SpeakOUT for a panel to discuss LGBTQIA voices and allyship in the workplace. We are committed to fostering a culture where we recognize our differences, inviting curiosity and inclusivity, so that everyone is valued, seen, and heard, and we look forward to continuing to celebrate, learn, and grow as allies of the LGBTQIA community. #Belong
-